OPTN/SRTR 2012 Annual Data Report: lung
- PMID: 24373171
- DOI: 10.1111/ajt.12584
OPTN/SRTR 2012 Annual Data Report: lung
Abstract
Lung transplants are increasingly used as treatment for end-stage lung diseases not amenable to other medical and surgical therapies. Lungs are allocated to adult and adolescent transplant candidates on the basis of age, geography, blood type compatibility, and the Lung Allocation Score, which reflects risk of wait-list mortality and probability of posttransplant survival. The overall median waiting time in 2012 was 4 months, and 65.3% of candidates underwent transplant within 1 year of listing; however, this proportion varied greatly by donation service area. Unadjusted median survival of lung transplant recipients was 5.3 years in 2012, and median survival conditional on living for 1 year posttransplant was 6.7 years. Among pediatric lung candidates in 2012, 32.1% were wait-listed for less than 1 year, 17.9% for 1 to less than 2 years, 16.7% for 2 to less than 4 years, and 33.3% for 4 or more years. Both graft and patient survival have continued to improve; survival rates for recipients aged 6-11 years are better than for younger recipients. Compared with recipients of other solid organ transplants, lung transplant recipients experienced the highest rates of rehospitalization for transplant complications: 43.7 per 100 patients in year 1 and 36.0 in year 2.
Keywords: End-stage lung diseases; Lung Allocation Score; lung transplant; organ allocation; transplant outcomes.
© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.
Similar articles
-
OPTN/SRTR 2013 Annual Data Report: lung.Am J Transplant. 2015 Jan;15 Suppl 2:1-28. doi: 10.1111/ajt.13200. Am J Transplant. 2015. PMID: 25626342
-
OPTN/SRTR 2013 Annual Data Report: kidney.Am J Transplant. 2015 Jan;15 Suppl 2:1-34. doi: 10.1111/ajt.13195. Am J Transplant. 2015. PMID: 25626344
-
OPTN/SRTR 2015 Annual Data Report: Lung.Am J Transplant. 2017 Jan;17 Suppl 1:357-424. doi: 10.1111/ajt.14129. Am J Transplant. 2017. PMID: 28052607
-
OPTN/SRTR 2018 Annual Data Report: Lung.Am J Transplant. 2020 Jan;20 Suppl s1:427-508. doi: 10.1111/ajt.15677. Am J Transplant. 2020. PMID: 31898416 Review.
-
OPTN/SRTR 2018 Annual Data Report: Heart.Am J Transplant. 2020 Jan;20 Suppl s1:340-426. doi: 10.1111/ajt.15676. Am J Transplant. 2020. PMID: 31898418 Review.
Cited by
-
Development of a biomimetic microfluidic oxygen transfer device.Lab Chip. 2016 Aug 16;16(17):3227-34. doi: 10.1039/c6lc00641h. Lab Chip. 2016. PMID: 27411972 Free PMC article.
-
Development and validation of the lung donor (LUNDON) acceptability score for pulmonary transplantation.Am J Transplant. 2023 Apr;23(4):540-548. doi: 10.1016/j.ajt.2022.12.014. Epub 2023 Jan 3. Am J Transplant. 2023. PMID: 36764887 Free PMC article.
-
Regenerative rehabilitation: a new future?Am J Phys Med Rehabil. 2014 Nov;93(11 Suppl 3):S73-8. doi: 10.1097/PHM.0000000000000211. Am J Phys Med Rehabil. 2014. PMID: 25310603 Free PMC article.
-
Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic.Am J Transplant. 2016 Oct;16(10):2836-2841. doi: 10.1111/ajt.13971. Epub 2016 Aug 24. Am J Transplant. 2016. PMID: 27438538 Free PMC article.
-
Lung donor shortage - how to overcome it?Kardiochir Torakochirurgia Pol. 2016 Sep;13(3):195-197. doi: 10.5114/kitp.2016.62603. Epub 2016 Sep 30. Kardiochir Torakochirurgia Pol. 2016. PMID: 27785130 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical